COMPANY

Acumen Pharmaceuticals

HQ: Newton, MA source · acumenpharm.com ↗ · New England

Acumen is advancing Enhanced Brain Delivery™ (EBD®) technology designed to increase the delivery of therapeutic antibodies across the blood-brain barrier (BBB). Acumen is building upon decades of research on toxic soluble amyloid beta oligomers (AβOs) to advance treatment options for Alzheimer’s disease (AD). From company website Source · Oct 13, 2026

Keywords: antibodies Alzheimer Disease sabirnetug sabirnetug (ACU193) ACU193

Profile checked Oct 10, 2026

$35.8MRaised (2 yrs)3Trials (company is sponsor)12NIH grants

Timeline

Mar 16, 2026 Raise Private placement: $35.75M (total, as published), announced Mar 16, 2026. Source: SEC filing. source ↗
Jun 25, 2024 Trial start Phase 1: A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants source ↗
Feb 29, 2024 Trial start Phase 2: A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD) source ↗
Jun 21, 2021 Trial start Phase 1: A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD source ↗

Upcoming milestones

2026-10 (ESTIMATED) · Phase 2 · A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD) · NCT06335173

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $35.8M. Last 2 years.

Mar 16, 2026 Private placement: $35.75M (total, as published), announced Mar 16, 2026. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT06335173	A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)	Phase 2	Active, not recruiting	Feb 29, 2024	2026-10 (estimated)
NCT06511570	A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants	Phase 1	Completed	Jun 25, 2024	Sep 17, 2024 (actual)
NCT04931459	A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD	Phase 1	Completed	Jun 21, 2021	Jun 12, 2023 (actual)

NIH awards 12

Annual award amounts. Total $7.3M.

Aug 10, 2020 NIH award 3U01AG053247-04S1 FY2020: $262,500 awarded for that fiscal year; activity U01 (OTHER_NIH); PI SIEMERS, ERIC; recipient as written: ACUMEN PHARMACEUTICALS, INC., Charlottesville, VA. Supplemental Grant Reque source ↗
Jul 1, 2020 NIH award 5U01AG053247-04 FY2020: $797,087 awarded for that fiscal year; activity U01 (OTHER_NIH); PI SIEMERS, ERIC; recipient as written: ACUMEN PHARMACEUTICALS, INC., Charlottesville, VA. Amyloid-Beta Oligomer Sele source ↗
Aug 16, 2019 NIH award 5U01AG053247-03 FY2019: $1,135,517 awarded for that fiscal year; activity U01 (OTHER_NIH); PI SIEMERS, ERIC; recipient as written: ACUMEN PHARMACEUTICALS, INC., Charlottesville, VA. Amyloid-Beta Oligomer Se source ↗
Aug 16, 2019 NIH award 5U01AG053247-03 FY2019: $1,135,517 awarded for that fiscal year; activity U01 (OTHER_NIH); PI IVES, JEFFREY L; recipient as written: ACUMEN PHARMACEUTICALS, INC., Charlottesville, VA. Amyloid-Beta Oligomer source ↗
Aug 31, 2018 NIH award 5U01AG053247-02 FY2018: $1,256,516 awarded for that fiscal year; activity U01 (OTHER_NIH); PI SIEMERS, ERIC; recipient as written: ACUMEN PHARMACEUTICALS, INC., Charlottesville, VA. Amyloid-Beta Oligomer Se source ↗
Aug 31, 2018 NIH award 5U01AG053247-02 FY2018: $1,256,516 awarded for that fiscal year; activity U01 (OTHER_NIH); PI IVES, JEFFREY L; recipient as written: ACUMEN PHARMACEUTICALS, INC., Charlottesville, VA. Amyloid-Beta Oligomer source ↗
Sep 15, 2017 NIH award 1U01AG053247-01A1 FY2017: $90,134 awarded for that fiscal year; activity U01 (OTHER_NIH); PI IVES, JEFFREY L; recipient as written: ACUMEN PHARMACEUTICALS, INC., Charlottesville, VA. Amyloid-Beta Oligomer S source ↗
Sep 15, 2017 NIH award 1U01AG053247-01A1 FY2017: $444,503 awarded for that fiscal year; activity U01 (OTHER_NIH); PI GOURE, WILLIAM; recipient as written: ACUMEN PHARMACEUTICALS, INC., Charlottesville, VA. Amyloid-Beta Oligomer S source ↗
Sep 15, 2017 NIH award 1U01AG053247-01A1 FY2017: $354,369 awarded for that fiscal year; activity U01 (OTHER_NIH); PI IVES, JEFFREY L; recipient as written: ACUMEN PHARMACEUTICALS, INC., Charlottesville, VA. Amyloid-Beta Oligomer source ↗
Sep 6, 2016 NIH award 1R41AG054337-01 FY2016: $222,192 awarded for that fiscal year; activity R41 (STTR); PI KLEIN, WILLIAM L; recipient as written: ACUMEN PHARMACEUTICALS, INC., Charlottesville, VA. Development of a non-fibrill source ↗
Sep 12, 2005 NIH award 1R43AG026951-01 FY2005: $183,750 awarded for that fiscal year; activity R43 (SBIR); PI KRAFFT, GRANT ARTHUR; recipient as written: ACUMEN PHARMACEUTICALS, INC., Livermore, CA. Drug discovery of anti-ADDL th source ↗
Jul 29, 2005 NIH award 1R43AG026190-01 FY2005: $145,774 awarded for that fiscal year; activity R43 (SBIR); PI KRAFFT, GRANT ARTHUR; recipient as written: ACUMEN PHARMACEUTICALS, INC., Livermore, CA. Biomarker for Alzheimer's Rela source ↗